PT-141 (Bremelanotide) for Men: Research, Uses, and What to Expect

If you have been researching options for erectile dysfunction or low libido, PT-141 may have come up alongside Viagra and Cialis. Unlike those medications, PT-141 (bremelanotide) works through a completely different pathway: the brain, not blood flow. That distinction matters, and it is why researchers began studying it specifically for men who do not get adequate results from conventional treatments.

This article explains how PT-141 works in men, what the clinical research shows, who it may be appropriate for, and what you need to know about dosing, side effects, and the important regulatory context around its use. This is not medical advice. Any treatment decision requires a conversation with a licensed healthcare provider who knows your medical history.

PT-141 is not FDA-approved for use in men. This article is for informational and educational purposes only. Consult a licensed healthcare provider before using any peptide therapy or considering any off-label treatment.

---

How PT-141 Works in Men

PT-141 (bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist. It binds primarily to MC4R (melanocortin 4 receptor), a receptor expressed in areas of the brain involved in sexual motivation and arousal.

This makes PT-141 fundamentally different from PDE5 inhibitors like sildenafil (Viagra) or tadalafil (Cialis). Those medications work peripherally, relaxing smooth muscle in penile vasculature to increase blood flow. PT-141 works centrally, activating desire and arousal circuits in the brain before any physical response occurs.

A 2023 review in Current Drug Targets (Maurya MR et al., PMID: 36366845) describes melanocortin receptors as emerging targets for sexual dysfunction precisely because they operate at the level of motivation rather than mechanics. If the challenge is reduced desire or psychogenic ED where the physical plumbing works but the brain is not initiating the signal, a centrally acting compound addresses the problem differently than a PDE5 inhibitor does.

PT-141 can also be used alongside tadalafil, because the two mechanisms are complementary rather than competing. One addresses desire and arousal signaling from the top down; the other addresses vascular readiness from the bottom up.

---

Clinical Evidence for PT-141 in Men

PT-141 has been studied in men with erectile dysfunction since the early 2000s, primarily in Phase II trials conducted before the FDA approval process narrowed to the women's indication.

A 2004 study published in the International Journal of Impotence Research (Rosen RC et al., PMID: 14999221) evaluated subcutaneous PT-141 in healthy men and in men who had an inadequate response to sildenafil. The study found that PT-141 produced measurable erectile responses and was well-tolerated across the groups studied, including those who had not responded adequately to Viagra.

A companion Phase II trial published the same year (Diamond LE et al., PMID: 14963471) used intranasal PT-141 in men with mild-to-moderate erectile dysfunction in a double-blind, placebo-controlled design. Participants reported improvements in erectile function, with tolerability data consistent with the subcutaneous study.

The most clinically significant finding for men who have already tried sildenafil comes from a 2008 randomized controlled trial published in the Journal of Urology (Safarinejad MR et al., PMID: 18206919). That study enrolled men who were identified as sildenafil non-responders and treated them with bremelanotide as a salvage approach. The randomized, double-blind, placebo-controlled design provides some of the strongest available evidence for PT-141's potential as a second-line option when PDE5 inhibitors are insufficient.

A 2005 study in Urology (Diamond LE et al., PMID: 15833522) also examined the co-administration of low-dose intranasal PT-141 with sildenafil in men with erectile dysfunction and found that the combination produced an enhanced erectile response compared to either agent alone, suggesting the two mechanisms work additively.

A foundational review published in the Annals of the New York Academy of Sciences (Molinoff PB et al., PMID: 12851303) provides the mechanistic underpinning of PT-141 as a melanocortin agonist and situates the compound within the broader biology of sexual response.

It is important to note that none of these studies led to FDA approval for men. PT-141's only FDA-approved indication is for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi. All clinical use in men is off-label.

---

*A licensed provider can evaluate whether PT-141 is an appropriate consideration for your individual situation.*

---

Who Might Benefit from PT-141

The research profile of PT-141 in men suggests it may be worth discussing with a provider in several specific situations:

Men who do not respond fully to sildenafil or tadalafil. The Safarinejad 2008 RCT was designed specifically for this population, making it the most directly applicable study for men who have tried first-line treatment.

Men with psychogenic erectile dysfunction. When ED has a significant psychological or motivational component rather than a purely vascular origin, a centrally acting compound may address a pathway that PDE5 inhibitors cannot. A review of central nervous system agents in male sexual dysfunction (Kumar R et al., PMID: 21621083) in the Urologic Clinics of North America describes this rationale in detail.

Men with low libido alongside testosterone deficiency. PT-141 may serve as an adjunct in men undergoing testosterone optimization who still experience low desire despite adequate hormone levels. The melanocortin pathway operates independently of testosterone signaling.

Men who cannot use PDE5 inhibitors due to nitrate medications. This is a critical safety consideration covered in the section on side effects below.

PT-141 is not studied or approved for any use in men and is not appropriate for everyone. A licensed provider must evaluate your health history before considering it.

---

Dosing and Administration

The FDA-approved dose of bremelanotide (Vyleesi, for women) is 1.75 mg administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. Off-label research in men has used comparable doses, though no approved protocol for men exists.

Administration: Subcutaneous injection into the abdomen or thigh.

Timing: Approximately 45 minutes before anticipated sexual activity. This is not a spontaneous, as-needed medication in the way oral ED drugs are often used.

Frequency: As needed. Not designed for daily dosing. Not recommended more than once in a 24-hour period.

Important: PT-141 is not FDA-approved for use in men. Off-label use involves compounded bremelanotide, which is not equivalent to, interchangeable with, or regulated under the same standards as FDA-approved Vyleesi. A licensed provider must evaluate whether any use is appropriate for your specific situation.

---

Side Effects in Men

The side effect profile observed in men's studies is consistent with what was later documented in the women's FDA approval program:

Nausea is the most commonly reported side effect, typically occurring within 1 to 2 hours of administration and resolving without intervention in most cases.

Flushing (warmth or redness, particularly of the face and neck) is also commonly reported.

Transient blood pressure increase occurs following administration. Blood pressure typically returns to baseline within 12 hours. This is a meaningful concern for men with hypertension or significant cardiovascular disease and requires provider evaluation.

Hyperpigmentation has been observed with extended use, involving darkening of the face, gums, or breasts. This was most apparent in people with darker skin tones and is a reason that extended or frequent use is not recommended.

Spontaneous erections have been reported in some men taking PT-141. It is worth noting that this reflects a different mechanism from Viagra. PT-141 can produce arousal signals without a physical stimulus because the effect originates in the brain rather than in vascular response.

Nitrate contraindication (important): PT-141 should not be used by men who take organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) for cardiovascular conditions. The combination can cause dangerous drops in blood pressure. This is a firm contraindication, not a relative caution. If you take any nitrate medication, tell your provider before discussing any treatment for ED.

---

PT-141 vs. Tadalafil for Men

Understanding when to use each approach, or whether to combine them, is a question best worked out with a provider. The key differences:

Tadalafil (Cialis) blocks PDE5, preventing the breakdown of cyclic GMP in penile tissue. This relaxes smooth muscle and increases blood flow, supporting erection during sexual stimulation. It has no direct effect on desire or arousal at the brain level.

PT-141 activates MC4R in the central nervous system, triggering desire and arousal signals before any physical response occurs. It does not directly affect penile blood flow.

Combined use: The 2005 Diamond et al. study found that low-dose PT-141 combined with sildenafil produced greater erectile response than either alone. This suggests the two approaches are additive. Some providers have explored combination protocols, though no standardized approach exists.

Who should avoid PT-141: Men taking nitrate medications (absolute contraindication), men with uncontrolled hypertension, and men with significant cardiovascular disease should not use PT-141 without explicit provider clearance.

---

Frequently Asked Questions

Does PT-141 work better than Viagra? These two compounds work differently and are not directly comparable. PT-141 acts centrally on arousal circuits; PDE5 inhibitors act peripherally on blood flow. For men whose ED has a significant psychogenic component, or who do not respond to PDE5 inhibitors, PT-141 represents a different mechanism rather than a superior one. A provider can help assess which approach may be appropriate for your situation.

Can I combine PT-141 with tadalafil? Research suggests the mechanisms are complementary. The Diamond 2005 study found enhanced response when PT-141 was combined with sildenafil. Whether combination is appropriate for you requires a provider evaluation, particularly given PT-141's blood pressure effects.

How long does PT-141 last? The pharmacokinetic data from Phase II studies suggests onset within 45 minutes, with effects typically lasting several hours. The blood pressure effect resolves within 12 hours.

Is PT-141 safe for men long-term? Long-term safety data in men is limited. Most studies were short-term Phase II trials. The women's approval program includes a 52-week safety extension, but those data were collected in a different population under a different protocol. Any consideration of extended use requires ongoing provider oversight.

---

Understanding the Off-Label Context

PT-141 received FDA approval only for HSDD in premenopausal women. Its use in men is entirely off-label and involves compounded bremelanotide, which is not approved by the FDA for any indication in men and has not gone through the same regulatory review as Vyleesi.

The clinical research in men is real and published in peer-reviewed journals, but it preceded FDA submission for the men's indication. The compound's development path focused on the women's indication. That means men considering PT-141 are using a compound with a clinical rationale, peer-reviewed data, and a known mechanism, but without an approved indication, without a standardized protocol, and with the uncertainty that comes with off-label compounded use.

A licensed provider can evaluate your individual situation, review your health history, and discuss whether any treatment options are appropriate for your specific case.

For context on PT-141's broader research history, see the [PT-141 research overview](/resources/pt-141-bremelanotide-sexual-health-research). If you are also exploring [PT-141 for women](/resources/pt-141-for-women), that article covers the FDA-approved indication in detail. Men exploring how [GLP-1 medications may affect erectile dysfunction](/resources/glp1-medications-erectile-dysfunction) will find a separate evidence base on that topic. For men considering combination approaches with [tadalafil online](/resources/tadalafil-online-how-to-get-a-prescription), or those pursuing [testosterone optimization](/resources/testosterone-optimization-evidence-based-approaches) as part of a broader sexual health strategy, those resources provide additional context.

---

*This article is for educational purposes only and does not constitute medical advice. PT-141 (bremelanotide) is not FDA-approved for use in men. Vyleesi (bremelanotide) is FDA-approved only for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded bremelanotide is not FDA-approved, is not the same as Vyleesi, and is not interchangeable with Vyleesi. Individual results vary. Consult your licensed healthcare provider before starting any treatment, particularly if you take nitrate medications or have cardiovascular disease. Prescriva is a Management Services Organization that provides administrative support to affiliated licensed providers. Treatment decisions are made by licensed providers in our affiliated network, not by Prescriva. This content references clinical trial data from research studies; compounded products have not been evaluated by the FDA for safety or efficacy.*

---

Sources

1. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. *International Journal of Impotence Research.* 2004;16(2):135-142. [PMID: 14999221](https://pubmed.ncbi.nlm.nih.gov/14999221/)

1. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. *International Journal of Impotence Research.* 2004;16(1):51-59. [PMID: 14963471](https://pubmed.ncbi.nlm.nih.gov/14963471/)

1. Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. *Urology.* 2005;65(4):755-759. [PMID: 15833522](https://pubmed.ncbi.nlm.nih.gov/15833522/)

1. Safarinejad MR. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. *Journal of Urology.* 2008;179(3):1066-1071. [PMID: 18206919](https://pubmed.ncbi.nlm.nih.gov/18206919/)

1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. *Annals of the New York Academy of Sciences.* 2003;994:96-102. [PMID: 12851303](https://pubmed.ncbi.nlm.nih.gov/12851303/)

1. Maurya MR, Tomar AS, Vinayak M. Melanocortin Receptors: Emerging Targets for the Treatment of Pigmentation, Inflammation, Stress, Weight Disorders and Sexual Dysfunction. *Current Drug Targets.* 2023;24(5):391-408. [PMID: 36366845](https://pubmed.ncbi.nlm.nih.gov/36366845/)

1. Kumar R, Alwaal A, Huynh LM, Yafi FA, Yoo JJ, Bhatt DL. Central nervous system agents and erectile dysfunction. *Urologic Clinics of North America.* 2011;38(2):165-172. [PMID: 21621083](https://pubmed.ncbi.nlm.nih.gov/21621083/)

Talk With a Provider

If PT-141 is something you want to explore further, the next step is a conversation with a licensed healthcare provider. A provider in our affiliated network can evaluate your individual situation, review your health history, and discuss whether any treatment options may be appropriate for your case.

*Consult your healthcare provider. Individual results vary. This is not medical advice.*

[Start Your Sexual Health Assessment](#)